DiaMedica Therapeutics Inc. - נכסים נקיים של החברה DMAC
The development of therapies for critical conditions remains independent of economic cycles, relying solely on biological factors. The current business resilience of DiaMedica Therapeutics (DMAC) is based on patent rights for the innovative DM199, although success depends on test results. High pricing power is driven by the uniqueness of the blood flow restoration method, and the metric stands at 0.04. The price history chart below illustrates the quotes for the company developing treatments for kidney failure and strokes.
DMAC (DiaMedica Therapeutics Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Professional managers utilize fundamental filters to distinguish speculative assets from reliable investments. This indicator reflects the company's net asset value minus all liabilities, determining the actual backing of each share. For DiaMedica Therapeutics (DMAC), which relies on investment prior to FDA drug approvals, this metric captures the volume of available resources. By analyzing the equity dynamics on the balance sheet, an investor assesses the financial cushion of the biotech startup.